Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 25,000 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the completion of the sale, the chief executive officer now owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. The transaction was disclosed in a filing with the SEC, which is available through this link.

Janux Therapeutics Price Performance

NASDAQ:JANX traded down $0.37 during trading hours on Friday, hitting $46.25. The stock had a trading volume of 541,000 shares, compared to its average volume of 721,396. The company has a 50 day simple moving average of $43.92 and a two-hundred day simple moving average of $44.52. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of -37.91 and a beta of 3.57. Janux Therapeutics, Inc. has a one year low of $5.65 and a one year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company’s revenue for the quarter was up 709.1% on a year-over-year basis. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 target price for the company. Scotiabank reduced their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research note on Monday, August 19th. Wedbush restated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research report on Monday, September 16th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $66.13.

Institutional Trading of Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in JANX. Amalgamated Bank lifted its stake in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the last quarter. Summit Securities Group LLC bought a new stake in Janux Therapeutics in the second quarter worth $29,000. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the second quarter worth $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Janux Therapeutics in the second quarter worth $151,000. Finally, Quest Partners LLC lifted its stake in Janux Therapeutics by 307.2% in the second quarter. Quest Partners LLC now owns 5,795 shares of the company’s stock worth $243,000 after purchasing an additional 4,372 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.